A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs

ISSN: 1874-0758 (Online)
ISSN: 1872-3128 (Print)

Volume 11, 4 Issues, 2017

Download PDF Flyer

Drug Metabolism Letters

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Zhiyang Zhao
Alliance Pharma
Malvern, PA

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs

Drug Metabolism Letters, 8(1): 19-30.

Author(s): Mehran F. Moghaddam, Yang Tang, Zhihong O’Brien, Samantha J. Richardson, Maria Bacolod, Prasoon Chaturedi, Julius Apuy and Ashutosh Kulkarni.

Affiliation: Department of Drug Metabolism and Pharmacokinetics, Celgene Corporation, 10300 Campus Point Dr, Suite 100, San Diego, CA 92121, USA.


The in vitro and in vivo preclinical ADME properties of 10 clinically late stage or marketed covalent inhibitors were evaluated in order to define advancement criteria for discovery of future drugs in this arena.

Our studies revealed the following: After incubating with S9 fractions for 30 minutes, the rat and human in vitro stability for these compounds ranged from 1% to 100%. The blood stability ranged from 30% to 100%. There was a broad range of CYP inhibition with prevalence for time-dependent inhibition of at least one enzyme. The Caco-2 permeability (A→B) ranged from negligible (0.6 x 10-6 cm/s) to highly permeable (31 x 10-6 cm/s) and the efflux ratio also varied widely (0.2-30). Most of the compounds were highly protein bound in both rat and human with binding ≥ 90%. Rat plasma clearance for the 10 compounds ranged from slow (11 mL/min/kg) to very rapid (350 mL/min/kg). The Vss ranged from low (0.67 L/kg) to very high (115 L/kg). MRT’s also ranged from short (0.5 hr) to long (7.4 hr). The oral exposures also showed a very broad range with Cmax’s ranging from 0.01-77 μM and exposure levels ranging from 0.03-106 μM.hr.

In conclusion, the wide range in in vitro and in vivo ADME data makes these particular ADME assays non-discriminatory in the selection of promising compounds. In our opinion, non-traditional assays such as target mass modification, target confirmation by amino acid sequencing, cellular target occupancy, and target turnover rate data in combination with the pharmacokinetic profiles are the critical considerations for progression of irreversible compounds in early discovery.

Biography: Mehran Moghaddam, PhD, is the head of Discovery DMPK at Celgene, a global biopharmaceutical company with products in oncology and immune-inflammatory related diseases. He has 18 years of industrial experience with DuPont, Pfizer, and Celgene. His expertise includes animal experimentation, pharmacokinetics, metabolism, metabolite/catabolite identification, and bioanalysis of small and macro-molecules.


ADME, covalent, discovery, irreversible, mass-modification, pharmacokinetics, screening.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 1
First Page: 19
Last Page: 30
Page Count: 12
DOI: 10.2174/1872312808666140317151735

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science